Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: October 2009

33 - Acute Pain Management in Sickle Cell Disease Patients

from SECTION III - Acute Pain Management in Special Patient Populations

REFERENCES

1. Nagel RL, Fabry ME, Billett HH, Kaul DK. Sickle cell painful crisis: a multifactorial event. Prog Clin Biol Res. 1987;361–380.
2. Noguchi CT, Torchia DA, Schechter AN. Intracellular polymerization of sickle hemoglobin: effects of cell heterogeneity. J Clin Invest. 1983;72:846–852.
3. Baez S, Kaul DK, Nagel RL. Microvascular determinants of blood flow behavior and HbSS erythrocyte plugging in microcirculation. Blood Cells. 1982;8:127–137.
4. Hebbel RP. Extracorpuscular factors in the pathogenesis of sickle cell disease. Am J Pediatr Hematol Oncol. 1982;4:316–319.
5. Kaul DK, Fabry ME, Windisch P, Baez S, Nagel RL. Erythrocytes in sickle cell anemia are heterogeneous in their rheological and hemodynamic characteristics. J Clin Invest. 1983;72:22–31.
6. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am. 2005;19:771–884.
7. Dampier C, Ely E, Eggleston B, Brodecki D, O’Neal P. Physical and cognitive-behavioral activities used in the home management of sickle pain: a daily diary study in children and adolescents. Pediatr Blood Cancer. 2004;43:674–678.
8. Elion JE, Brun M, Odievre MH, Lapoumeroulie CL, Krishnamoorthy R. Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium. Hematol J. 2004;5(suppl 3):195–198.
9. Okpala I. Leukocyte adhesion and the pathophysiology of sickle cell disease. Curr Opin Hematol. 2006;13:40–44.
10. Okpala I. The intriguing contribution of white blood cells to sickle cell disease – a red cell disorder. Blood Rev. 2004;18:65–73.
11. Schnog JB, Mac Gillavry MR, van Zanten AP, et al. Protein C and S and inflammation in sickle cell disease. Am J Hematol. 2004;76:26–32.
12. Dover GJ, Charache S. The effect of increased fetal hemoglobin production on the frequency of vaso-occlusive crisis in sickle cell disease. Prog Clin Biol Res. 1987;240:277–285.
13. Vichinsky EP, Lubin BH. Sickle cell anemia and related hemoglobinopathies. Pediatr Clin North Am. 1980;27:429–447.
14. Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol. 2005;129:482–490.
15. Ejindu VC, Hine AL, Mashayekhi M, Shorvon PJ, Misra RR. Musculoskeletal manifestations of sickle cell disease. Radiographics. 2007;27:1005–1021.
16. Onuba O. Bone disorders in sickle-cell disease. Int Orthop. 1993;17:397–399.
17. Kim SK, Miller JH. Natural history and distribution of bone and bone marrow infarction in sickle hemoglobinopathies. J Nucl Med. 2002;43:896–900.
18. Shapiro B, Dinges DF, Orne EC. Recording of crisis pain in sickle cell disease. Adv Pain Res Ther. 1990;313–321.
19. Vichinsky EP, Johnson R, Lubin BH. Multidisciplinary approach to pain management in sickle cell disease. Am J Pediatr Hematol Oncol. 1982;4:328–333.
20. Rao KR, Patel AR, Shah PC, Vohra RM. Sickle cell dactylitis. Arch Intern Med. 1980;140:439.
21. Worrall VT, Butera V. Sickle-cell dactylitis. J Bone Joint Surg Am. 1976;58:1161–1163.
22. Stevens MC, Padwick M, Serjeant GR. Observations on the natural history of dactylitis in homozygous sickle cell disease. Clin Pediatr (Phila). 1981;20:311–317.
23. Watson RJ, Burko H, Megas H, Robinson M. The handfoot syndrome in sickle-cell disease in young children. Pediatrics. 1963;31:975–982.
24. Foucan L, Ekouevi D, Etienne-Julan M, Salmi LR, Diara JP. Early onset dactylitis associated with the occurrence of severe events in children with sickle cell anaemia. The Paediatric Cohort of Guadeloupe (1984–99). Paediatr Perinat Epidemiol. 2006;20:59–66.
25. Lutzker LG, Alavi A. Bone and marrow imaging in sickle cell disease: diagnosis of infarction. Semin Nucl Med. 1976;6:83–93.
26. Mankad VN, Williams JP, Harpen MD, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood. 1990;75:274–283.
27. Rao VM, Fishman M, Mitchell DG, et al. Painful sickle cell crisis: bone marrow patterns observed with MR imaging. Radiology. 1986;161:211–215.
28. Aloui N, Nessib N, Jalel C, et al. Febrile osseous pain in children with sickle cell disease: MRI findings. J Radiol. 2005;86:1693–1697.
29. Keeley K, Buchanan GR. Acute infarction of long bones in children with sickle cell anemia. J Pediatr. 1982;101:170–175.
30. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294.
31. Quinn CT, Shull EP, Ahmad N, Lee NJ, Rogers ZR, Buchanan GR. Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood. 2007;109:40–45.
32. Sarnaik SA, Ballas SK. Molecular characteristics of pediatric patients with sickle cell anemia and stroke. Am J Hematol. 2001;67:179–182.
33. Ballas SK. Current issues in sickle cell pain and its management. Hematol Am Soc Hematol Educ Progr. 2007;2007:97–105.
34. Walco GA, Dampier CD. Pain in children and adolescents with sickle cell disease: a descriptive study. J Pediatr Psychol. 1990;15:643–658.
35. Beyer JE, Aradine CR. Content validity of an instrument to measure young children's perceptions of the intensity of their pain. J Pediatr Nurs. 1986;1:386–395.
36. Szyfelbein SK, Osgood PF, Carr DB. The assessment of pain and plasma beta-endorphin immunoactivity in burned children. Pain. 1985;22:173–182.
37. Finley GA, McGrath PJ. Measurement of pain in infants and children. Seattle, WA: IASP Press; 1998.
38. Manworren RC, Hynan LS. Clinical validation of FLACC: preverbal patient pain scale. Pediatr Nurs. 2003;29:140–146.
39. Grunau RV, Craig KD. Pain expression in neonates: facial action and cry. Pain. 1987;28:395–410.
40. Katz ER, Kellerman J, Siegel SE. Behavioral distress in children with cancer undergoing medical procedures: developmental considerations. J Consult Clin Psychol. 1980;48:356–365.
41. Dampier C, Ely E, Brodecki D, O’Neal P. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J Pediatr Hematol Oncol. 2002;24:643–647.
42. Dampier C, Ely B, Brodecki D, O’Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 2002;3:461–470.
43. Thomas VJ, Hambleton I, Serjeant G. Psychological distress and coping in sickle cell disease: comparison of British and Jamaican attitudes. Ethn Health. 2001;6:129–136.
44. Luffy R, Grove SK. Examining the validity, reliability, and preference of three pediatric pain measurement tools in African-American children. Pediatr Nurs. 2003;29:54–59.
45. Johnson CS. The acute chest syndrome. Hematol Oncol Clin North Am. 2005;19:857,79, vi–vii.
46. McGrath PA. Pain in the pediatric patient: practical aspects of assessment. Pediatr Ann. 1995;24:126, 33, 137–138.
47. McGrath PA. Psychological aspects of pain perception. Arch Oral Biol. 1994;39(suppl):55S–62S.
48. McGrath PA. Evaluating a child's pain. J Pain Symptom Manage. 1989;4:198–214.
49. Varni JW, Thompson KL, Hanson V. The Varni/Thompson Pediatric Pain Questionnaire. I. Chronic musculoskeletal pain in juvenile rheumatoid arthritis. Pain. 1987;28:27–38.
50. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine (Baltimore). 2005;84:363–376.
51. McGrath PA. The multidimensional assessment and management of recurrent pain syndromes in children. Behav Res Ther. 1987;25:251–262.
52. McGrath PA, Speechley KN, Seifert CE, et al. A survey of children's acute, recurrent, and chronic pain: validation of the pain experience interview. Pain. 2000;87:59–73.
53. McGrath PJ, Johnson GG. Pain management in children. Can J Anaesth. 1988;35:107–110.
54. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83–89.
55. Raphael RI. Pathophysiology and treatment of sickle cell disease. Clin Adv Hematol Oncol. 2005;3:492–505.
56. Payne R. Pain management in sickle cell disease: rationale and techniques. Ann N Y Acad Sci. 1989;565:189–206.
57. Buckalew V Jr, Someren A. Renal manifestations of sickle cell disease. Arch Intern Med. 1974;133:660–669.
58. Alcorn R, Bowser B, Henley EJ, Holloway V. Fluidotherapy and exercise in the management of sickle cell anemia: a clinical report. Phys Ther. 1984;64:1520–1522.
59. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. Cochrane Database Syst Rev. 2007;2:CD005406.
60. Embury SH, Garcia JF, Mohandas N, Pennathur-Das R, Clark MR. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med. 1984;311:291–295.
61. Schulman LL. Oxygen therapy in sickle-cell anemia. N Engl J Med. 1984;311:1319–1320.
62. Zipursky A, Robieux IC, Brown EJ, et al. Oxygen therapy in sickle cell disease. Am J Pediatr Hematol Oncol. 1992;14:222–228.
63. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139:785–789.
64. Thurston GB, Henderson NM, Jeng M. Effects of erythrocytapheresis transfusion on the viscoelasticity of sickle cell blood. Clin Hemorheol Microcirc. 2004;30:83–97.
65. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322:1617–1621.
66. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol. 2007;82:255–265.
67. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease: National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855–1865.
68. Benjamin LJ, Berkowitz LR, Orringer E, et al. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood. 1986;67:1442–1447.
69. Temple JD, Harrington WJ, Ahn YS, Rosenfeld E. Treatment of sickle cell disease with danazol. J Fla Med Assoc. 1986;73:847–848.
70. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med. 1990;323:366–372.
71. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Lacroix L, Bunn HF. Hydroxyurea and erythropoietin therapy in sickle cell anemia. Semin Oncol. 1992;19:74–81.
72. Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol. 1989;32:104–111.
73. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555–2565.
74. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317–1322.
75. Dover GJ, Charache S. Stimulation of fetal hemoglobin production by hydroxyurea in sickle cell anemia. Prog Clin Biol Res. 1989;316B:295–306.
76. Dover GJ, Charache S. Chemotherapy and hemoglobin F synthesis in sickle cell disease. Ann N Y Acad Sci. 1989;565:222–227.
77. Dover GJ, Charache S, Boyer SH, Vogelsang G, Moyer M. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood. 1985;66:527–532.
78. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Cost-effectiveness of hydroxyurea in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol. 2000;64:26–31.
79. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89:1078–1088.
80. Vichinsky EP, Lubin BH. A cautionary note regarding hydroxyurea in sickle cell disease. Blood. 1994;83:1124–1128.
81. Ren H, Obike I, Okpala I, Ghebremeskel K, Ugochukwu C, Crawford M. Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2005;72:415–421.
82. Ren H, Okpala I, Ghebremeskel K, Ugochukwu CC, Ibegbulam O, Crawford M. Blood mononuclear cells and platelets have abnormal fatty acid composition in homozygous sickle cell disease. Ann Hematol. 2005;84:578–583.
83. Oh IH, Fabry ME, Humphries RK, et al. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells. Exp Hematol. 2004;32:461–469.
84. Mitchell MJ, Lemanek K, Palermo TM, Crosby LE, Nichols A, Powers SW. Parent perspectives on pain management, coping, and family functioning in pediatric sickle cell disease. Clin Pediatr (Phila). 2007;46:311–319.
85. Shapiro BS. The management of pain in sickle cell disease. Pediatr Clin North Am. 1989;36:1029–1045.
86. Burghardt-Fitzgerald DC. Pain-behavior contracts: effective management of the adolescent in sickle-cell crisis. J Pediatr Nurs. 1989;4:320–324.
87. Zeltzer L, Dash J, Holland JP. Hypnotically induced pain control in sickle cell anemia. Pediatrics. 1979;64:533–536.
88. Erickson CJ. Applications of cyberphysiologic techniques in pain management. Pediatr Ann. 1991;20:145, 146, 148–150, 152–156.
89. Cozzi L, Tryon WW, Sedlacek K. The effectiveness of biofeedback-assisted relaxation in modifying sickle cell crises. Biofeedback Self Regul. 1987;12:51–61.
90. Bodhise PB, Dejoie M, Brandon Z, Simpkins S, Ballas SK. Non-pharmacologic management of sickle cell pain. Hematology. 2004;9:235–237.
91. Dinges DF, Whitehouse WG, Orne EC, et al. Self-hypnosis training as an adjunctive treatment in the management of pain associated with sickle cell disease. Int J Clin Exp Hypn. 1997;45:417–432.
92. Holbrook CT, Phillips G. Natural history of sickle cell disease and the effects on biopsychosocial development. J Health Soc Policy. 1994;5:7–18.
93. Jay S, Elliott CH, Fitzgibbons I, Woody P, Siegel S. A comparative study of cognitive behavior therapy versus general anesthesia for painful medical procedures in children. Pain. 1995;62:3–9.
94. Yoon SL, Black S. Comprehensive, integrative management of pain for patients with sickle-cell disease. J Altern Complement Med. 2006;12:995–1001.
95. Wang WC, George SL, Wilimas JA. Transcutaneous electrical nerve stimulation treatment of sickle cell pain crises. Acta Haematol. 1988;80:99–102.
96. Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med. 1992;116:364–368.
97. Clare N. Management of sickle cell disease: management would improve if doctors listened more to patients. BMJ. 1998;316:935.
98. Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage. 1997;14:168–174.
99. Day SW. Development and evaluation of a sickle cell assessment instrument. Pediatr Nurs. 2004;30:451–458.
100. Ballas SK. Management of sickle pain. Curr Opin Hematol. 1997;4:104–111.
101. Ballas SK. Sickle cell disease: clinical management. Clin Haematol 1998;11:185–214.
102. Ballas SK. Ethical issues in the management of sickle cell pain. Am J Hematol. 2001;68:127–132.
103. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am. 2005;19:785, 802, v.
104. Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R. Opportunities to improve outcomes in sickle cell disease. Am Fam Physician. 2006;74:303–310.
105. Nagel RL. The challenge of painful crisis in sickle cell disease. JAMA. 2001;286:2152–2153.
106. Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Management of vaso-occlusive pain in children with sickle cell disease. J Pediatr Hematol Oncol. 2003;25:307–311.
107. Moussavou A, Vierin Y, Eloundou-Orima C, Mboussou M, Keita M. Sickle cell disease pain management following the World Health Organization's protocol. Arch Pediatr. 2004;11:1041–1045.
108. Dunlop RJ, Bennett KC. Pain management for sickle cell disease. Cochrane Database Syst Rev. 2006;2:CD003350.
109. Agble YM. Management of sickle cell disease: non-addictive analgesics can be as effective as morphine and pethidine. BMJ. 1998;316:935.
110. Beyer JE, Simmons LE. Home treatment of pain for children and adolescents with sickle cell disease. Pain Manag Nurs. 2004;5:126–135.
111. Shapiro BS, Dinges DF, Orne EC, et al. Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance. Pain. 1995;61:139–144.
112. Pollack CV Jr, Sanders DY, Severance HW Jr. Emergency department analgesia without narcotics for adults with acute sickle cell pain crisis: case reports and review of crisis management. J Emerg Med. 1991;9:445–452.
113. Simckes AM, Chen SS, Osorio AV, Garola RE, Woods GM. Ketorolac-induced irreversible renal failure in sickle cell disease: a case report. Pediatr Nephrol. 1999;13:63–67.
114. Erhan E, Inal MT, Aydinok Y, Balkan C, Yegul I. Tramadol infusion for the pain management in sickle cell disease: a case report. Paediatr Anaesth. 2007;17:84–86.
115. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188.
116. Goodman E. Use of ketorolac in sickle-cell disease and vaso-occlusive crisis. Lancet. 1991;338:641–642.
117. Hardwick W Jr, Givens TG, Monroe KW, King WD, Lawley D. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999;15:179–182.
118. de Franceschi L, Finco G, Vassanelli A, Zaia B, Ischia S, Corrocher R. A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain. Haematologica. 2004;89:1389–1391.
119. Eke FU, Obamyonyi A, Eke NN, Oyewo EA. An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis. Trop Med Int Health. 2000;5:81–84.
120. Beiter JL, Jr, Simon HK, Chambliss CR, Adamkiewicz T, Sullivan K. Intravenous ketorolac in the emergency department management of sickle cell pain and predictors of its effectiveness. Arch Pediatr Adolesc Med. 2001;155:496–500.
121. Perlin E, Finke H, Castro O, et al. Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol. 1994;46:43–47.
122. Dayer P, Collart L, Desmueles J. The pharmacology of tramadol. Drugs. 1994;47:3–7.
123. Martin WR. Pharmacology of opioids. Pharmacol Rev. 1983;35:283–323.
124. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81:429–444.
125. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:983–1013.
126. Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr. 2007;150:623–626.
127. Richardson P, Steingart R. Meperidine and ketorolac in the treatment of painful sickle cell crisis. Ann Emerg Med. 1993;22:1639–1640.
128. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol. 1983;13:180–185.
129.Meperidine usage in patients with sickle cell crisis. Ann Emerg Med. 1986;15:1506–1508.
130. Abbuhl S, Jacobson S, Murphy JG, Gibson G. Serum concentrations of meperidine in patients with sickle cell crisis. Ann Emerg Med. 1986;15:433–438.
131. Hagmeyer KO, Mauro LS, Mauro VF. Meperidine-related seizures associated with patient-controlled analgesia pumps. Ann Pharmacother. 1993;27:29–32.
132. Nadvi SZ, Sarnaik S, Ravindranath Y. Low frequency of meperidine-associated seizures in sickle cell disease. Clin Pediatr (Phila). 1999;38:459–462.
133. Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg MM. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med. 1977;86:738–741.
134. Tang R, Shimomura S, Rotblatt M. Meperidine induced seizures in sickle cell patients. Hosp Form. 1980;76:764–772.
135. Perlman KM, Myers-Phariss S, Rhodes JC. A shift from demerol (meperidine) to dilaudid (hydromorphone) improves pain control and decreases admissions for patients in sickle cell crisis. J Emerg Nurs. 2004;30:439–446.
136. Gonzalez ER, Ornato JP, Ware D, Bull D, Evens RP. Comparison of intramuscular analgesic activity of butorphanol and morphine in patients with sickle cell disease. Ann Emerg Med. 1988;17:788–791.
137. Lunzer MM, Yekkirala A, Hebbel RP, Portoghese PS. Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia. Proc Natl Acad Sci USA. 2007;104:6061–6065.
138. Martin WR. Opioid antagonists. Pharmacol Rev. 1967;19:463–521.
139. Martin WR. Pharmacologic factors in relapse and the possible use of the narcotic antagonists in treatment. IMJ Ill Med J. 1966;130:489–494.
140. Romagnoli A, Keats AS. Ceiling respiratory depression by dezocine. Clin Pharmacol Ther. 1984;35:367–373.
141. Romagnoli A, Keats AS. Ceiling effect for respiratory depression by nalbuphine. Clin Pharmacol Ther. 1980;27:478–485.
142. Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. Drugs. 2002;62:1143–1172.
143. Woods GM, Parson PM, Strickland DK. Efficacy of nalbuphine as a parenteral analgesic for the treatment of painful episodes in children with sickle cell disease. J Assoc Acad Minor Phys. 1990;1:90–92.
144. Connelly NR, Rahimi A, Parker RK. Nalmefene or naloxone for preventing intrathecal opioid mediated side effects in cesarean delivery patients. Int J Obstet Anesth. 1997;6:231–234.
145. Kendrick WD, Woods AM, Daly MY, Birch RFH, DiFazio C. Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus. Anesth Analg. 1996;82:641–647.
146. Dickerhoff R, von Ruecker A. Pain crises in patients with sickle cell diseases: pathogenesis, clinical aspects, therapy. Klin Padiatr. 1995;207:321–325.
147. Forbes K, Hanks GW, Justins DM, Cherry DA. Sickle cell pain crisis. Lancet. 1996;347:262.
148. Kotila TR. Management of acute painful crises in sickle cell disease. Clin Lab Haematol. 2005;27:221–223.
149. Meltzer BA. Sickle cell pain crisis. Lancet. 1996;347:262.
150. Simini B. Sickle cell pain crisis. Lancet. 1996;347:261–262.
151. Stinson J, Naser B. Pain management in children with sickle cell disease. Paediatr Drugs. 2003;5:229–241.
152. Ward SJ. Sickle cell pain crisis. Lancet. 1996;347:261.
153. Cole TB, Sprinkle RH, Smith SJ, Buchanan GR. Intravenous narcotic therapy for children with severe sickle cell pain crisis. Am J Dis Child. 1986;140:1255–1259.
154. Conti C, Tso E, Browne B. Oral morphine protocol for sickle cell crisis pain. Md Med J. 1996;45:33–35.
155. Wagner MC, Eckman JR, Wick TM. Histamine increases sickle erythrocyte adherence to endothelium. Br J Haematol. 2006;132:512–522.
156. Dunlop RJ, Bennett KC. Pain management for sickle cell disease. Cochrane Database Syst Rev. 2006;2:CD003350.
157. Kotila TR. Management of acute painful crises in sickle cell disease. Clin Lab Haematol 2005;27:221–223.
158. Shapiro BS, Cohen DE, Howe CJ. Patient-controlled analgesia for sickle-cell-related pain. J Pain Symptom Manage. 1993;8:22–28.
159. Ballas SK, Viscusi ER, Epstein KR. Management of acute chest wall sickle cell pain with nebulized morphine. Am J Hematol. 2004;76:190–191.
160. Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation. Pediatr Hematol Oncol. 1992;9:317–326.
161. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997;350:1358–1361.
162. Dumaplin CA. Avoiding admission for afebrile pediatric sickle cell pain: pain management methods. J Pediatr Health Care. 2006;20:115, 122; quiz 123–125.
163. Eaton ML, Haye JS, Armstrong FD, Pegelow CH, Thomas M. Hospitalizations for painful episodes: association with school absenteeism and academic performance in children and adolescents with sickle cell anemia. Issues Compr Pediatr Nurs. 1995;18:1–9.
164. Epstein K, Yuen E, Riggio JM, Ballas SK, Moleski SM. Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc. 2006;98:1109–1113.
165. Powers RD. Management protocol for sickle-cell disease patients with acute pain: impact on emergency department and narcotic use. Am J Emerg Med. 1986;4:267–268.
166. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501–504.
167. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499–506.
168. Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Quantification of analgesic use in children with sickle cell disease. Clin J Pain. 2007;23:8–14.
169. Ives TJ, Guerra MF. Constant morphine infusion for severe sickle cell crisis pain. Drug Intell Clin Pharm. 1987;21:625–627.
170. Harrison JF, Liesner R, Davies SC. Pethidine in sickle cell crisis. BMJ. 1992;305:182.
171. Nagar S, Remmel RP, Hebbel RP, Zimmerman CL. Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Dispos. 2004;32:98–104.
172. D’Sa S, Parker N. Fast track admission for children with sickle cell crises. Opiates other than pethidine are better. BMJ. 1998;316:934–935.
173. Berde CB, Lehn BM, Yee JD, Sethna NF, Russo D. Patient-controlled analgesia in children and adolescents: a randomized, prospective comparison with intramuscular administration of morphine for postoperative analgesia. J Pediatr. 1991;118:460–466.
174. Brozovic M, Davies SC, Yardumian A, Bellingham A, Marsh G, Stephens AD. Pain relief in sickle cell crisis. Lancet. 1986;2:624–625.
175. McPherson E, Perlin E, Finke H, Castro O, Pittman J. Patient-controlled analgesia in patients with sickle cell vaso-occlusive crisis. Am J Med Sci. 1990;299:10–12.
176. McDonald AJ, Cooper MG. Patient-controlled analgesia: an appropriate method of pain control in children. Paediatr Drugs. 2001;3:273–284.
177. Rusy LM, Olsen DJ, Farber NE. Successful use of patient-controlled analgesia in pediatric patients 2 and 3 years old: two case reports. Am J Anesthesiol. 1997;14:212–214.
178. Dix HM. New advances in the treatment of sickle cell disease: focus on perioperative significance. ***AANA J. 2001;69:281–286.
179. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs patient-controlled analgesia for sickle cell crisis pain: comparison in patients in the emergency department. Arch Intern Med. 1991;151:1373–1378.
180. Holbrook CT. Patient-controlled analgesia pain management for children with sickle cell disease. J Assoc Acad Minor Phys. 1990;1:93–96.
181. Melzer-Lange MD, Walsh-Kelly CM, Lea G, Hillery CA, Scott JP. Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care. 2004;20:2–4.
182. Schechter NL, Berrien FB, Katz SM. PCA for adolescents in sickle-cell crisis. Am J Nurs. 1988;88:719, 721–722.
183. Schechter NL, Berrien FB, Katz SM. The use of patient-controlled analgesia in adolescents with sickle cell pain crisis: a preliminary report. J Pain Symptom Manage. 1988;3:109–113.
184. Shapiro BS, Cohen DE, Howe CJ. Patient-controlled analgesia for sickle-cell-related pain. J Pain Symptom Manage. 1993;8:22–28.
185. Buchanan ID, Woodward M, Reed GW. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatr Blood Cancer. 2005;45:716–724.
186. Kopecky EA, Jacobson S, Joshi P, Koren G. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther. 2004;75:140–146.
187. Finer P, Blair J, Rowe P. Epidural analgesia in the management of labor pain and sickle cell crisis – a case report. Anesthesiology. 1988;68:799–800.
188. McHardy P, McDonnell C, Lorenzo AJ, Salle JL, Campbell FA. Management of priapism in a child with sickle cell anemia; successful outcome using epidural analgesia. Can J Anaesth. 2007;54:642–645.
189. Labat F, Dubousset AM, Baujard C, Wasier AP, Benhamou D, Cucchiaro G. Epidural analgesia in a child with sickle cell disease complicated by acute abdominal pain and priapism. Br J Anaesth. 2001;87:935–936.
190. Yaster M, Tobin JR, Billett C, Casella JF, Dover G. Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis. Pediatrics. 1994;93:310–315.
191. McHardy P, McDonnell C, Lorenzo AJ, Salle JL, Campbell FA. Management of priapism in a child with sickle cell anemia; successful outcome using epidural analgesia. Can J Anaesth. 2007;54:642–645.
192. Williams RM, Moskowitz DW. The prevention of pain from sickle cell disease by trandolapril. J Natl Med Assoc. 2007;99:276–278.
193. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330:733–737.
194. de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception. 1997;56:313–16.
195. Ahn YS, Fernandez LF, Kim CI, et al. Danazol therapy renders red cells resistant to osmotic lysis. FASEB J. 1989;3:157–162.
196. Anie KA. Psychological complications in sickle cell disease. Br J Haematol. 2005;129:723–729.
197. Benton TD, Ifeagwu JA, Smith-Whitley K. Anxiety and depression in children and adolescents with sickle cell disease. Curr Psychiatry Rep. 2007;9:114–121.
198. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104:570–587.
199. Richebe P, Rivat C, Laulin JP, Maurette P, Simonnet G. Ketamine improves the management of exaggerated postoperative pain observed in perioperative fentanyl-treated rats. Anesthesiology. 2005;102:421–428.
200. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005;103:147–155.
201. Schechter NL. The undertreatment of pain in children: an overview. Pediatr Clin North Am. 1989;36:781–794.
202. Elander J, Marczewska M, Amos R, Thomas A, Tangayi S. Factors affecting hospital staff judgments about sickle cell disease pain. J Behav Med. 2006;29:203–214.
203. Labbe E, Herbert D, Haynes J. Physicians’ attitude and practices in sickle cell disease pain management. J Palliat Care. 2005;21:246–251.
204. Pack-Mabien A, Labbe E, Herbert D, Haynes J, Jr. Nurses’ attitudes and practices in sickle cell pain management. Appl Nurs Res. 2001;14:187–192.
205. Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage. 1997;14:168–174.
206. Brozovic M, Davies SC, Yardumian A, Bellingham A, Marsh G, Stephens AD. Pain relief in sickle cell crisis. Lancet. 1986;2:624–625.
207. Silbergleit R, Jancis MO, McNamara RM. Management of sickle cell pain crisis in the emergency department at teaching hospitals. J Emerg Med. 1999;17:625–630.
208. Tetrault SM, Scott RB. Five-year retrospective study of hospitalization and treatment of patients with sickle cell anemia. South Med J. 1976;69:1314–1316.
209. American Pain Society. Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. Glenview, IL: American Pain Society; 1999.